AFT Pharmaceuticals (NZE:AFT, ASX:AFP) reported a net loss after tax of NZ$2.4 million for the six months to September, compared with a net profit of NZ$1.8 million in the year-earlier period on the back of demand disruptions, according to a Thursday filing with the New Zealand and Australian bourses.

Operating revenue rose 4% to NZ$86.7 million, owing to double-digit sales growth in Australasia. Revenue in international and Asian markets fell due to reduced demand from key customers.

Fiscal 2025 operating profit is expected to range from NZ$15 million to NZ$20 million, which AFT Pharmaceuticals Chair David Flacks said is lower than the company's expectations at the start of the year.

AFT Pharmaceuticals' shares were up nearly 3% in recent Thursday trade in New Zealand.

Price (AUD): $2.61, Change: $+0.07, Percent Change: +2.76%